Ruth Ramos Diaz
Overview
Explore the profile of Ruth Ramos Diaz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Del Rosario Garcia B, Morales Barrios J, Cruz Jurado J, Diaz R, Vina Romero M, Padron I, et al.
J Oncol Pharm Pract
. 2022 Dec;
29(7):1613-1618.
PMID: 36482704
Objectives: Imatinib is the first therapeutic option for the treatment of unresectable or metastatic gastrointestinal stromal tumours. Previous studies have shown an improvement in patient survival rates following the use...
2.
Del Rosario Garcia B, Gonzalez Garcia I, Vina Romero M, Gonzalez Garcia J, Diaz R, Padron I, et al.
J Oncol Pharm Pract
. 2021 Oct;
29(1):40-44.
PMID: 34661491
Introduction: The addition of imatinib to the therapeutic arsenal for chronic myeloid leukaemia (CML) has changed the natural course of the disease, in such a way that it is now...
3.
Pena-Cabia S, Royuela Vicente A, Diaz R, Gutierrez Nicolas F, Penalver Vera A, Siso Garcia I, et al.
Biomed Pharmacother
. 2021 Jun;
141:111827.
PMID: 34153845
Limited literature is available for bevacizumab exposure-response relationship and there is not a concentration threshold associated with an optimal disease control. This prospective observational study in patients with metastatic colorectal...
4.
Del Rosario Garcia B, Morales Barrios J, Vina Romero M, Diaz R, Nazco Casariego G, Jimenez Sosa A, et al.
J Oncol Pharm Pract
. 2021 Mar;
28(3):530-534.
PMID: 33645328
Introduction: Patient-reported outcomes (PROs) use, via a computer registry, allows patients to report their symptoms enabling the detection of early signs of progression of the disease. For such a record,...
5.
Padron I, Gonzalez Garcia J, Diaz R, Ceballos Lenza I, Gutierrez Nicolas F
J Oncol Pharm Pract
. 2020 Sep;
27(6):1354-1356.
PMID: 32873135
Introduction: Trastuzumab is a monoclonal antibody which could induce the activation of a humoral immune response generating anti-drug antibodies (ADAs). Such response depends of the protein nature and the route...
6.
Vina-Romero M, Diaz R, Gonzalez Garcia J, Nazco-Casariego G, Diaz-Vera J, Gutierrez-Nicolas F
J Oncol Pharm Pract
. 2020 Aug;
27(5):1102-1105.
PMID: 32854574
Asparaginase (ASNase) use as a tumour-inhibitor drug has changed completely the natural course of paediatric acute lymphoblastic leukaemia (ALL) in such a way that it represents a paradigm shift in...
7.
Gonzalez Garcia J, Gutierrez Nicolas F, Diaz R, Nazco Casariego G, Vina Romero M, Llabres Martinez M, et al.
Ann Pharmacother
. 2020 Jan;
54(8):775-779.
PMID: 31971005
Subcutaneous trastuzumab (T-SC) administration does not allow the historical target concentration of 20 µg/mL for efficacy to be reached, from the start of treatment in patients with a body mass...
8.
Gutierrez Nicolas F, Nazco Casariego G, Vina Romero M, Gonzalez Garcia J, Diaz R, Perez Perez J
Eur J Hosp Pharm
. 2019 Jun;
23(3):131-133.
PMID: 31156833
Introduction: The advent of Luer-type needleless venous access catheters has been accompanied by a growing number of catheter-related bloodstream infections. Our main objective was to compare rates of colonisation and...
9.
Garcia Gil S, Diaz R, Nazco Casariego G, Llanos Munoz M, Vina Romero M, Martin Calero B, et al.
Med Clin (Barc)
. 2018 Mar;
151(11):425-430.
PMID: 29499902
Background And Objectives: Evaluate the relationship between the presence of polymorphisms in genes involved in the pharmacodynamics of irinotecan (UGT1A, SLCO1B1, ABCB1 and ABCC2) and the safety of irinotecan in...
10.
Gonzalez Garcia J, Gutierrez Nicolas F, Nazco Casariego G, Batista Lopez J, Ceballos Lenza I, Diaz R, et al.
Ann Pharmacother
. 2017 Jun;
51(11):976-980.
PMID: 28643558
Background: Plasma concentrations of trastuzumab <20 µg/mL in patients with gastric cancer are associated with reduced progression-free and overall survival. In breast cancer treatment, this relationship has not yet been...